Using chemical genetic screening and pre-clinical model studies, researchers have discovered that inducing ubiquitin-mediated degradation of mutant EZH2 could provide a more effective treatment strategy for haematologic malignancies.
List view / Grid view
Chronic lymphocytic leukaemia (CLL)
Researchers identified the inhibitor JQ1 as a potential drug to improve immune response to CAR T-cell therapies in leukaemia patients.
A team of researchers in Spain show for the first time the complete epigenome of chronic lymphocytic leukaemia, the most common type of leukaemia.
Researchers have discovered the reason why some patients with advanced chronic lymphocytic leukaemia (CLL) don't respond to chimeric antigen receptor (CAR) T cell therapy...